Because biosimilars are relatively new to the United States, drug makers pursuing FDA approval for biosimilars seek additional information about the kinds and quantities of evidence that the agency uses to approve these therapies.
The European Union has swiftly outpaced the United States in the number of biosimilar therapies that it has approved for marketing; the FDA has only approved 7 biosimilars to date, though many additional molecules are being developed with the US market in mind. Because biosimilars are relatively new to the United States, drug makers pursuing FDA approval for biosimilars seek additional information about the kinds and quantities of evidence that the agency uses to approve these therapies.
A new review, appearing in the Journal of Managed Care and Specialty Pharmacy, assesses the evidence that was used in the first 5 biosimilar approvals: filgrastim-sndz (Zarxio), infliximab-dybb (Inflectra), adalimumab-atto (Amjevita), etanercept-szzs (Erelzi), and infliximab-abda (Renflexis). The review draws on data derived from drug-specific FDA approval documents, webcasts, and advisory committee votes; reference product information; evidence used for the extrapolation of indications; and evidence used to demonstrate similarity in terms of analytic and functional characteristics, pharmacokinetics (PK), pharmacodynamics (PD), efficacy, safety, and immunogenicity.
The review’s authors identified 6 key issues from their data:
Finally, the authors note that FDA advisory committee meetings may be slowing the process of biosimilar approval, and suggest that only those biosimilars that have “specific issues” that would warrant convening a committee be subject to such proceedings. The review identifies a second challenge specific to US biosimilar uptake: the long interval between product approval and market availability, which is a phenomenon largely tied to lengthy patent litigation between reference product sponsors and biosimilar developers.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.